» Articles » PMID: 39271260

Deep Learning-based Multimodal Spatial Transcriptomics Analysis for Cancer

Overview
Journal Adv Cancer Res
Publisher Elsevier
Specialty Oncology
Date 2024 Sep 13
PMID 39271260
Authors
Affiliations
Soon will be listed here.
Abstract

The advent of deep learning (DL) and multimodal spatial transcriptomics (ST) has revolutionized cancer research, offering unprecedented insights into tumor biology. This book chapter explores the integration of DL with ST to advance cancer diagnostics, treatment planning, and precision medicine. DL, a subset of artificial intelligence, employs neural networks to model complex patterns in vast datasets, significantly enhancing diagnostic and treatment applications. In oncology, convolutional neural networks excel in image classification, segmentation, and tumor volume analysis, essential for identifying tumors and optimizing radiotherapy. The chapter also delves into multimodal data analysis, which integrates genomic, proteomic, imaging, and clinical data to offer a holistic understanding of cancer biology. Leveraging diverse data sources, researchers can uncover intricate details of tumor heterogeneity, microenvironment interactions, and treatment responses. Examples include integrating MRI data with genomic profiles for accurate glioma grading and combining proteomic and clinical data to uncover drug resistance mechanisms. DL's integration with multimodal data enables comprehensive and actionable insights for cancer diagnosis and treatment. The synergy between DL models and multimodal data analysis enhances diagnostic accuracy, personalized treatment planning, and prognostic modeling. Notable applications include ST, which maps gene expression patterns within tissue contexts, providing critical insights into tumor heterogeneity and potential therapeutic targets. In summary, the integration of DL and multimodal ST represents a paradigm shift towards more precise and personalized oncology. This chapter elucidates the methodologies and applications of these advanced technologies, highlighting their transformative potential in cancer research and clinical practice.

Citing Articles

Progressive role of artificial intelligence in treatment decision-making in the field of medical oncology.

Bongurala A, Save D, Virmani A Front Med (Lausanne). 2025; 12:1533910.

PMID: 40018354 PMC: 11865077. DOI: 10.3389/fmed.2025.1533910.

References
1.
Chen Q, Li M, Chen C, Zhou P, Lv X, Chen C . MDFNet: application of multimodal fusion method based on skin image and clinical data to skin cancer classification. J Cancer Res Clin Oncol. 2022; 149(7):3287-3299. DOI: 10.1007/s00432-022-04180-1. View

2.
Hu B, Sajid M, Lv R, Liu L, Sun C . A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology. Front Immunol. 2022; 13:996721. PMC: 9659855. DOI: 10.3389/fimmu.2022.996721. View

3.
Johnson K, Wei W, Weeraratne D, Frisse M, Misulis K, Rhee K . Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci. 2020; 14(1):86-93. PMC: 7877825. DOI: 10.1111/cts.12884. View

4.
Wang J, Li B, Luo M, Huang J, Zhang K, Zheng S . Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. Signal Transduct Target Ther. 2024; 9(1):83. PMC: 10991592. DOI: 10.1038/s41392-024-01779-3. View

5.
Chang Y, He F, Wang J, Chen S, Li J, Liu J . Define and visualize pathological architectures of human tissues from spatially resolved transcriptomics using deep learning. Comput Struct Biotechnol J. 2022; 20:4600-4617. PMC: 9440291. DOI: 10.1016/j.csbj.2022.08.029. View